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tion and current status of the IP ecosystem in South Africa. It provides a 
technical-legal but also a socio-political assessment of the circumstances, 
political positions, and vital jurisprudential advances that South Africa has 
implemented vis a vis the critical challenges for Public Health it faced with 
communicable diseases, especially vih aids. A brief comparative account of 
the regulations in the neighbouring countries is provided with the necessary 
reference to India, which has been influential in the local developments as 
well as in the continental import patterns. An indication of the regulation 
and practices in the countries of the sadc region was included as a compara-
tive exercise examining the existing legislation and procedures. Additionally, 
the regulatory evolution of India was mentioned as it is one of the primary 
providers of patented and generic medicines, but also a referent for the 
legislative and jurisprudential development of the Southern Africa region. 
Keywords. Intellectual property; Pharmaceuticals; Patents; Southern Africa; sadc; Pub-
lic Health; Universal Cover; Public Policy; trips; hiv, aids; Communicable Diseases.
regulación de la propiedad intelectual en sudáfrica- evolución, 
estado actual y comparación con los países de la región sadc 
(comunidad de desarrollo de los países de áfrica meridional)
resumen
Este artículo revisa y analiza de manera crítica el desarrollo de las regulaciones de 
propiedad intelectual relacionadas con patentes de productos farmacéuticos en Sudá-
frica con un enfoque particular en los casos clave que han dado forma a la evolución 
y al estado actual del ecosistema de propiedad intelectual en patentes en Sudáfrica. 
En el documento se encontrará una evaluación técnico-jurídica pero también una 
narración sociopolítica de las circunstancias, posiciones políticas y avances jurispru-
denciales clave que han dado forma a la respuesta de Sudáfrica frente a los grandes 
retos en materia de enfermedades comunicables y de salud pública, en especial de 
vih- sida que ha debido enfrentar en las últimas décadas. Un breve recuento de 
las regulaciones y prácticas en los países de la región sadc ha sido incluido como 
ejercicio comparativo examinando la legislación y los procedimientos adelantados. 
Adicionalmente, se ha agregado la necesaria mención de India, ya que además de 
ser uno de los principales proveedores de medicamentos patentados y genéricos, ha 
sido un referente para la evolución legislativa y jurisprudencial de la región. 
Palabras clave: Propiedad intelectual; Farmacéuticos; Patentes; África meridional; 
sadc; Salud pública; Cobertura universal; Política pública; trips; vih; sida; En-
fermedades comunicables. 
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1. introduction
Intellectual property is the area of the law that concerns itself with the protection 
of a persons’ ideas, forms of expression, and inventions. Intellectual Property 
Rights (iprs) can appear to be government protection of innovation and creativity, 
whereby the person holding such a right obtains the power to exclude all others 
from certain activities relating to such intellectual property.1 A patent is a specific 
type of ipr, which applies to any new invention involving an inventive step and 
which is capable of being2 used in trade or industry or agriculture.3 This paper 
will give a detailed analysis of ip regulations for pharmaceutical companies and 
access to medicines in South Africa compared to other countries on the continent.
The article starts with a deep account of the narratives informing the South 
African ip regulations for pharmaceutical during and post-apartheid, which are 
necessary to understand the country’s vicissitudes in the area. Apartheid has in-
fluenced all aspects of life in South Africa, and intellectual property was not the 
exception. The way political decisions post-apartheid in the world of intellectual 
property have been shaped has a lot to do with the effects of the former regime in 
the public health system and the emergency caused by the hiv epidemic, which, 
in turn, can trace its roots to the social structure orchestrated and implemented 
by the apartheid regime. 
It then will go through the regulations in South Africa with the necessary 
reference to India, as it had influence on the recent South African regulations and 
has informed policy and the executive. It subsequently revises the regulations and 
touches on the policy of Botswana, Zimbabwe, Malawi, Namibia, and Zambia to 
establish the status of the sadc countries in comparable matters. The paper closes 
its revision on the Least Developed countries regime with a short commentary.
A conclusion of the findings is presented in a summary. 
2. timeline of the ip regulations  
for pharmaceuticals in south africa
This timeline is presented in two sections: pre and during apartheid and post-
apartheid. The reasoning behind this division is the depth of the political influence 
in South Africa’s industrial development, ip protection, regulation, and public 
policy. In a way, the post-apartheid government was deliberate about divesting 
1 E. Su, ‘The Winners and Losers: trips and its Effect on Developing Countries’, 
hjil 1 (2000) 172-3




3 Section 25 of the Patents Act of 57 1978
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from the areas with the prior regime was heavily invested, especially if the matters 
had an ideological component to it, which intellectual property had. 
On this point, it is pertinent to highlight that the ip regulations commenced 
in South Africa in 1916, shortly after the Natives Land Act of 1913, which was 
the seminal regulation dispossessing non-whites of land and property rights and 
was the foundational basis for the apartheid regime that was to come a few decades 
later. This context is important because it gives clarity about the policy decisions 
taken during and post-apartheid.
Another mention that may provide a wider context and further understanding 
of the timeline to be presented below is the fact that the apartheid regime designed, 
planted, and fermented the public health emergency that exploded during the 
beginning of the new South Africa due to the brutal separation of families created 
by the working structures in manufacturing and mining facilities enforced by the 
apartheid government. Such social structure encouraged the exponential spread 
of hiv and fostered many unhealthy practices in terms of nutrition, sexuality, 
cohabitation, and education among non-whites. South Africans are still paying, 
literally, with their lives for the consequences of this social design. 
The division below is, therefore, not merely an arbitrary collection of data 
separated in time, but the radiography from a particular point of view – the IP 
regulatory environment - of a society that has undergone profound transforma-
tions, not all of which have been beneficial. 
2. 1 During Apartheid
– Intellectual Property Laws before trips
Increased cross border trade required patent protection in other countries, and 
national patent laws4 of the 18th and 19th centuries were disparate.5 Some of the 
regulations did not allow patent protection for foreign products while others pre-
vented patents already patented, on the basis that there was no novelty.6 Different 
rules, languages, rigorous deadlines, and other impediments unique to international 
contexts with the publication of a patent specification in specific places destroying 
novelty exacerbated the problem.7 
4 L. Ndlovu, Access to Medicines Under the World Trade Organization trips Agree-
ment: A Comparative Study of sadc Countries, University of South Africa, May (2014) at 
200 (Unpublished lld Thesis). Available at: http://uir.unisa.ac.za/bitstream/handle/10500/14185/
thesis_ndlovu_l.pdf?sequence=1 
5 S. Koshy, ‘The Effect of trips on Indian Patent Law: A Pharmaceutical Industry 
Perspective’, Journal of Science and Technology 4 (1995) 1.
6 H. Hestermeyer, Human Rights and the wto: The case of Patents and Access to 
Medicines (2007) 34.
7 Ibid.
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By 1 January 1995, when trips came into existence at the wto, the Paris 
Convention had already been ratified by 129 states.8 Developing countries were 
hesitant to sign the Paris Convention. This was due to rational doubts regarding 
technical capabilities, technical assistance and the ingenuity of the Convention.9 
On the other hand, under gatt, intellectual property was a lawful restriction to 
trade.10 Therefore, most of these international treaties before trips promoted 
unilateralism, which would in all likelihood be unmanageable and hinder access 
to medicines.
– South African Patent Laws
The first patent legislation that regulated Pharmaceuticals in South Africa was The 
Patents, Designs, Trademarks, and Copyright Act of 1916. One novel provision 
of the aforementioned legislation was that, rather than just having a monopoly 
of a patent for a 20 years term, the Act allowed for an extension in exceptional 
circumstances. The provision for an extension is found in section 50 of the Act.11 
Section 51 went on to provide-
“(1) The court shall, in considering its decision, have regard to the nature and 
merits of the invention in relation to the public and to the profits made by the 
patentee as sum and to all the circumstances of the case.
(2) The Court, if it is of the opinion that the patentee has been inadequately 
remunerated by his patent, may order the extension of the term of the patent for 
a further term.”
The underlying policy of the Patents Act is that a patent represents a quid pro 
quo.12 In Letraset Ltd13, Holmes JA described that-
“The quid is the monopoly conferred upon the patentee for a number of years. 
The quo is the new knowledge which he presents to the public, and which, after 
the expiry of the patent, will be available for general utilisation.” 14
The legislation, therefore, enabled the patentee to apply for an extension of the 
patent if they were of the view that the product had not made expected monetary 
returns in comparison to what was invested in its research and being put on the 
market. This provision found its way to the 1978 Act15. Section 46 (1) of the Act 
purports that the term of a patent granted is 20 years with no allowance for an 
extension. It was provided in s 3(1) (d), however, that a patent granted on an ap-
8 Ibid.
9 C.M. Correa and A.A. Yusuf, Intellectual Property and International Trade: The 
trips Agreement (eds) (2008) at 36.
10 Article xxiv (d) of gatt 1947.
11 The Patents, Designs, Trademarks and Copyright Act of 1916. 
12 See also Steyn CJ in the Voet case at 330H – 331A.
13 Letraset Ltd. v Helios Ltd. 1977 (3) SA 254 (A).
14 Ibid. para 344H.
15 The Patent Act of 1978.
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plication made before the commencement of the 1978 Act should be subject to 
provisions of section 39 of the repealed Act.
By a subsequent amendment s1(1) of the Patents Amendment Act 14 of 1979, 
the term of a patent granted under the repealed law was not to be extended for a 
period exceeding five years. The extension provisions of the Act were designed to 
meet the case when the quid is inadequate when measured against the quo, the 
benefits conferred by the invention on the public.16
– Case Law
South Africa recognized this quid pro quo in the case law and established criteria to 
calculate whether the monetary gains (or losses) had been adequate to the patentee, 
even after repealing the provisions in the act. 
– South African Druggists Ltd v Bayer AG17
One of the cases that included the extension of the patent in its claims is the Bayer 
case. On 20 March 1967, Bayer filed in Germany a patent application for a phar-
maceutical product. Thereafter corresponding patent applications were presented 
in several countries, including the Republic of South Africa, where the patent was 
granted. The regular term of the patent expired on 8 March 1984. No application 
to amend the patent specification was made until almost the date of expiry. 18 On 
19 August 1983, Bayer made an application, in terms of s 39 (1) (a) of the Patent 
Act 37 of 1952 (“the repealed Act”) read with s 3 (1) of the Patent Act 57 of 1978 
(“the Act”) for the extension of the term of the patent for 5 years. The application 
for extension was opposed by South African Druggists (sad). One of the grounds 
for the opposition was that the patent was invalid based on lack of novelty and 
that a limited extension should not be granted because it would circumvent the 
statutory requirement relating to the amendment of the patent specifications.19 
Section 39 of the Act lays down the functions of the Commissioner to determine 
the facts whether the applicant has not derived adequate remuneration. Corbett JA 
in South African Railways and Harbour20 envisaged that proof that the patentee has 
not derived adequate remuneration from the patent is, then, the foundation for the 
Commissioner’s discretionary power to grant an extension of the term. Two of the 
principles considered to determine adequate remuneration is the principle of lost 
time and fault. In our present case, the Commissioner and the Appellate Division 
found that the respondent had lost sufficient compensation due to lost time and 
16 See (n15) Para 387bh.
17 South African Druggists Ltd v Bayer, ag 1988 sa 519 (T).
18 Para 249ef.
19 Ibid, para 41H.
20 South African Railways and Harbour v Standard Truck Co 1982 (1) sa 806 (A) 
at 818H- 819A.
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extended the period of the patent for one year. It is noteworthy to observe that this 
is less than the period lost because of obtaining registration. A blind application 
of simple proportion would no doubt be open to criticism. Proper remuneration 
would not ordinarily come in at a steady rate from the first to the last day of a 
patent’s term, and an additional year’s monopoly after 1964 was not necessarily 
equivalent in commercial value with a year lost during the previous decade.21
2.2 Post-Apartheid
The application of IP laws evolved within the wider system which excluded and 
oppressed non-white majorities. Redressing, dignity restorations and reparations 
were at the forefront of the new regime’s priorities. The new government was 
painfully aware of the fact that the entirety of the legal construct in South Africa 
was infected by racist policies which needed deconstruction and re-design for 
an inclusive, non-racial government to succeed in the creation, application, and 
enforcement of norms, with sufficient legitimacy which should be underpinned 
by a refreshed concept of justice. This led to incorrect decisions in the prevention, 
mitigation, and management of the hiv/aids situation as mentioned above. 
Due to the complexity of the existing framework and the weight of the eco-
nomic interests around it, the evolution of the legal framework still has essential 
flaws as illustrated below. Some costly mistakes in policy-making regarding intel-
lectual property laws were made by the post-apartheid government. This is can 
be seen in keeping a set of rules without amendments, leaving the country in 
the position of having a framework even more protective than the international 
agreements it had subsequently signed, which resulted in reinforced protection of 
patents, evergreening, and weakening fundamental concepts.
– Othering and the Psychology of Shame
The position that states take in the international sphere on health and intellec-
tual property (IP) policy matters is influenced by their national experience and 
positions. Based on an analysis of literature written in the first decade of the 20th 
century, Loewenson, Modisenyane and Pearcey22 identified Africa’s key narratives 
to be those of ‘unity and Ubuntu’, ‘liberation ethics and demands of nationhood’ 
and ‘development aid or development policy.’
The meta norms of Ubuntu places communal interests as a key component 
of individual, interpersonal, and group relations and transactions in its quest to 
achieve ‘humaneness, social justice, and fairness’.23 It has resonance across the 
21 Para 1082H as per Wessels ja.
22 R. Loewenson et al ‘Africa Perspectives in global health Diplomacy’ Journal of 
Health Diplomacy (2) 1 p.6- 11
23 S v Makwanyane (1995) 3 SA 391 cc 246.
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continent and has been documented as a core value in Botswana, Lesotho, Ma-
lawi, Mozambique, Namibia, South Africa, Swaziland, Zambia and Zimbabwe.24 
One of the reasons why African states unified was to fight colonisation and seek 
liberation or independence.25 Strong bonds of interdependence were built between 
states as they supported each other’s liberation efforts through providing refuge for 
exiles, together with military training and other support for those actively involved 
in armed struggle. The support came mostly from the states26 which supported 
South Africa’s ousting of Apartheid.27 This mutual support has not ended with the 
demise of colonisation, but has continued to inform African states’ continental 
initiatives and foreign policy positions28 in a not always successful attempt of pan 
Africanism and regional integration. In particular, there has been a sense that the 
world has failed to pay enough attention to meeting the medical needs of Africans, 
such as the provision of antiretrovirals,29 and that the global IP system has some 
regrettable neo-colonial aspects.30
trips bears the brunt of such critiques, as it is the primary articulation of the 
global IP system. These findings contend that an underlying attitude of “othering” 
pervades all discussions about what the law should and should not be to address 
access to medicines for hiv/aids of various categories of States. While hiv/aids is 
always under the limelight, it is just one of the many ailments that gravely affect 
African countries while the international IP system seems to continue to support a 
colonial mindset that keeps “othering” people from the global south based on their 
economic performance, which in the view of some African law and policymakers 
is simply untenable. 
Othering refers to a process by which individuals and society view and label people 
who are different in a way that devalues them.31 It operates across multiple dimensions 
to reinforce a conception of virtuous ‘Self ’ and lesser ‘Other’.32 Certain people are 
determined as “not us” and that determination ‘function to create a devalued and 
dehumanized Other,” and distancing of the Other from ourselves.33 This affects 
how we view such persons’ needs and interests.
24 M. Letseka, Urban and Justice as Fairness’, Mediterranean Journal of Social Sciences 
(2014) 5 (9) 544- 547; c.b.n Gade, ‘The Historical Development of the written discourses 
on Ubuntu’ Afr J Philos (2011) 30 (3) p 303- 309.
25 Loewenson et al (note 20) 8.
26 Angola, Botswana, Mozambique, Tanzania, Zambia, and Zimbabwe.
27 Loewenson et al (note 20) 8.
28 LJ, ‘Sovereignty and the African Union’, Journal Part African Studies (2012) 93 at 97.
29 Loewenson et al (note 20) 8.
30 A. Rahmatian ‘Neo- Colonial Aspects of Global Intellectual Property Protection’, 
Journal of World Intellectual Property (2009) 12 (1) at 40- 47.
31 S.J. Stabile, ‘Othering and the Law’ University of S.T Thomas Law Journal (14) 2 
(2016) 381. Othering and the Law. Available at https://ir.stthomas.edu/cgi/viewcontent.
cgi?article=1369&context=ustlj 
32 J. Todres, Law, Otherness, and Human Trafficking, Santa Clara Law Review 
(2009) 49 609.
33 Ibid at 614.
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The psychologist Erik Erikson34 purports that those who are not us come to 
be scorn not only as different but less than us. It is noteworthy to envisage that 
even when othering does not lead to the commission of horrendous acts against 
those who are labeled as others, it quite often has the effect of excluding others 
from our locus of concern.35 One example brought by researchers is the reaction 
to reporting of atrocities in Africa. With respect to the genocide in Rwanda, there 
is a very poignant scene in the 2005 movie Hotel Rwanda where Don Cheadle - 
playing the Hotel manager, who risked his life trying to save as many Tutsis as he 
could - suggests that once the West has seen news reports of what is happening, they 
will stop it. Surely, he says, once they see what is going on, they will not allow it to 
continue. The answer from the seasoned reporter is straight and sharp. He says: “It’s 
simple, African lives are not seen as valuable as the lives of Europeans or Americans.”
It was of paramount importance to provide a detailed analysis of the concept of 
othering because what follows is an examination of attitudes of leaders of African 
states towards antiretroviral treatments and Western pharmaceutical companies 
in Africa. Renwick36 maintains that it was this hostility towards white certainties 
that led the post-apartheid South African government at the time to move towards 
denialism about aids.
Government officials, having read documentation from ‘experts dissidents,’ 
concluded that hiv did not cause aids. It was believed that the framing of the 
problem was related to racist attitudes about Africans and to the determination of 
Western pharmaceutical companies to “force” African governments to purchase 
“unaffordable treatments.”37 The idea that dominated saw reality with the lenses 
of the aforementioned Western Reporter, which is, “if the lives of Africans are not 
valuable to the eyes of Americans or Europeans, then why suddenly do they seem 
to matter?” It is within these contexts that the West only cared about making huge 
profits from arvs and not the lives of Africans. Though the government’s refusal 
to supply antiretroviral drugs to pregnant women to prevent transmission of the 
disease to their children resulted in many tens of thousands of avoidable deaths, 
one should purport that those claims, despite being scientifically void and danger-
ous, were not unfounded. This is so considering that a majority of South Africans 
thought of testing for hiv (the needle) and antiretrovirals as “poisons” brought by 
the white man to wipe all Africans. This subject shall be analysed below.
South African courts ordered the government to make antiretrovirals available 
to pregnant women.38 Yet in 2003, the government had declarations in the media 
34 E. Erikson, Ghandi’s Truth on the Origins of Militant Nonviolence. WW Norton 
(1969) 431.
35 T. Shakespeare, Choices and Rights: Eugenics, Genetics and Disability Equality, 
Disability & Soc’ Y (1998) 13 665- 669.
36 R. Renwick, How to Steal a Country: State Capture and Hopes for the Future of 
South Africa, Jamaica Media (2018) 14.
37 Ibid at 17.
38 Ibid at 19.
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indicating that high government officials did not know anyone who died of aids. 
These declarations were even though some anc (African National Congress, the 
government party) Members of Parliament were taking arv drugs denied to others. 
The president’s spokesperson, Parks Mankahlana, died of aids, as did the President 
of anc Youth League (ancyl), Peter Mokaba. President Mandela declared that one 
of his sons had died of aids. Yet none of this affected the official denialism, with 
a document circulated by official sources “claiming that Mankahlana had died 
from the arvs he was taking and not from aids.”39 The two times Sunday Times 
Alan Paton Award winner, Jonny Steinberg, went on a three-year research on the 
accessibility of arv treatment program in deep rural areas of the Eastern Cape in 
2005. The program was run by an msf (Médecins Sans Frontieres) doctor called 
Hermann Reuter. His work was that of a medical missionary: he wanted to show 
that you could provide suitable aids treatment anywhere, even in places that had 
long ago been routed, and if you did so, people would come forward.40 
An important finding of the research from the people, about hiv testing and 
the arv programme is summed up by one msf activist named Kate Marrandi: 
“In 2003, Dr Hermann came. He started telling us he got help - arvs. Nobody 
believed him. Some said, “this one has come to kill the people”. Even the doctors 
did not believe him. People thought he had come to destroy the people with his 
needle and his blood test. They believed aids was caused by politics, by white 
people.”41 In the collective imaginary, the origin of the epidemic was not brewed 
by witches and their demons, but in the vividly imagined laboratories of Western 
Science.42 Therefore, from Steinberg’s findings, rage, and denialism, was all over 
South Africa, especially in rural areas. Where there is aids, there is blame. Hence 
the now thwarted belief that the virus was hatched in laboratories, to be let loose 
on blacks until whites became the electoral majority.43 The reality is, that transmis-
sion of hiv was exacerbated by two main facts. One was the social architecture of 
the country, where men were separated from their families, constantly wandering 
through temporary dwellings in the industrial centres and while doing so engaging 
in multiple sexual relations, including a high amount of exposure to sex workers, 
to later return to their rural places of origin infecting their wives. The second 
one was the tardy and disconnected action from the government, which, due to 
the political context explained above, was also plagued with distrust towards the 
pharmaceutical sector, lack of reliable scientific council internally, late regulation 
of arv distribution, plus a myriad of political nuances.
39 Declarations of government officials in the media available at: https://www.iol.co.za/
news/politics/i-know-no-one-whos-died-of-aids-says-mbeki-113561. 
40 J. Steinberg, The Three Letter Plague: A Young Man’s Journey through a great 
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Having navigated through the complexities of the South African scenario with 
a brief history and contextualization, it is possible to move onto the next chapter 
which will provide a review of the regulatory framework, the case law, and the 
current state of the law, the policy, the political postures, and the jusrisprudence 
in some of the relevant aspects related to patents in South Africa. Such an intro-
duction will enable further comparison with African countries of the sadc region 
and India, where many similarities, examples, and learnings can and have been 
drawn in this area of the law. 
3. the existing landscape: regulatory framework,  
relevant decisions of domestic courts and critical  
matters and salient issues
trips
Cynthia Ho44 has authored a comprehensive book about trips and its controversial 
implementation. It is observed from the book that the World Trade Organiza-
tion (wto) membership requires acceptance of trips binding signatories to its 
terms.45 The wto structure provides a landmark in international trade dispute 
resolution by creating the Dispute Settlement Understanding and an impartial 
Dispute Resolution Panel, through which violations of trips can be raised.46 One 
national government can initiate action against another and allege that the op-
posing government has breached any wto agreement.47 If the Dispute Resolution 
Panel encounters that a provision of the agreement has been violated or that there 
is nullification or impairment of rights (Art xxiii gatt), it applies a remedy similar 
to the ones in contracts: the party in breach must either perform, pay damages, 
or expect retaliation.48 Specific penalties for a trips violations has a substantial 
impact on developing countries.
The implementation of trips changed the substantive laws in developing 
countries that previously had no significant patent laws or excluded medicines 
from patentability.49 Threatening with trade sanctions, the wto enforcement 
mechanism allowed larger nations to ‘coerce’ developing countries to modify 
44 C.M Ho, Current Controversies Concerning Patent Rights and Public Health in 
a world of International Norms, in Patent Law Theory: A Handbook of Contemporary 
Research, Tokisho Takaneka eds (2008) 673 p 673- 674.
45 Ibid at 673. See also E. Wisser, Simulating Pharmaceutical Markets In The Deve-
loping World: The Problems with “Pull” Funding Mechanisms. Available at http://www.
bu.edu/ilj/files/2014/05/note_wisser.pdf 
46 Ibid 679. See also See also E. Wisser, Simulating Pharmaceutical Markets In The 




49 Ho, at (note 42) at 677.
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their systems and meet their obligations in full awareness that smaller countries 
do not have sufficient leverage to correspond to larger – and wealthier- nations in 
an equivalent manner. It is within this realm that it has been entailed above that 
trips is purported to have neo-colonial aspects. Therefore, after trips came into 
effect, developing nations expressed concern that implementing the substantive 
patent rights required by trips, including patent protection of pharmaceuticals, 
could have significant public health consequences.50 In response, the wto issued 
the Doha Declaration in 2001.
The Doha Declaration
The Doha Declaration was an attempt to balance the interests of developing and 
developed countries. It does so by stating that the trips Agreement should not 
prevent members from taking measures to protect public health and to instead 
promote access to medicines for all.51 Provisions of this sort were already in exis-
tence in previous wto agreements such as Art. xx of gatt.
The Doha Declaration, therefore, provided much-needed flexibility, by laying 
down specific trips flexibilities that could be utilised by developing countries, such 
as the issuing of compulsory licenses, allowing parallel importation, “determining 
of itself what constitutes as a national health emergency.”52
The trips flexibilities have become utilised by many developing countries 
(such as India and Brazil), whereas in others, such as South Africa, they are yet 
to be taken advantage of. This may be because South Africa did not have to cre-
ate and implement an ip regulation system from scratch in order to meet trips 
commitments, as it already had a working IP protection environment when trips 
came into force, and thus it was a matter of adapting and tweaking the existing 
structure, which may have blurred the need for the use of these tools.
The South African patent legislation contains crippling weaknesses.53 They have 
been attributed to the absence of an examination system, some trips-plus provi-
sions, the absence of pre and post-grant opposition procedures for patent applications, 
a weak definition of novelty which allows evergreening and the absence of an express 
provision dealing with parallel imports in the relevant legislation.54 
50 Ibid, at 676.
51 S.B. Meyer, ‘A Healthy Solution for patients and patents: How India’s Legal Victory 
against pharmaceutical giant reconciles human rights with intellectual property rights’ 
vjetl (2008) 10 3 at 771.
52 A. Kapezynski, ‘Harmonisation and its discontent: A core study of trips Imple-
mentation in India’s Pharmaceutical Sector’ clr (2009) 1579.
53 L.L. Gonzalez, ‘Evergreening Keeps Products Costly: Patents Review Proposal 
Could Slash Drug Prices’ Cape Times, 10 September 2013 at 4.
54 This complaint is misplaced because section 15C of the Medicines and Related 
Substances Control Amendment Act of 1997 does provide for the parallel importation 
of medicines, albeit, in a roundabout incoherent manner. See Ndlovu (n6).
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In the context of access to medicines, evergreening, which has been identi-
fied as the main contributor to high cost of medicines (because it prevents the 
access of generics to the market), is considered a weak point of the Patents Act.55 
Therefore, it seems a natural conclusion that South Africans will be able to access 
their right to health, succinctly described out in section 27 of the Constitution 
if evergreening and some of the matters noted below are properly addressed.56 
The regulatory architecture is composed by the Patents Act57, as amended by the 
Intellectual Property Law Amendment Act58, the Patents Amendment Act59, the 
Medicines and Related Substances Control Act60, as amended by the Medicines 
and Related Substances Control Amendment Act61 and the 2002 Medicines and 
Related Substances Amendment Act62, and the Competition Act63. In this section, 
the implications of the Patent Act, the Medicines and Related Substances Control 
Act, the Competition Act and provisions of the National Intellectual Policy will be 
discussed, while considering relevant decisions of domestic courts from the High 
Court to the Constitutional Court.
Patent Act 
According to section 46 of the Patent Act of 1978, patents in South Africa are 
granted for 20 years for inventions that are new and they involve an inventive step 
and are useful in trade, industry, or agriculture. The provision is seemingly in accord 
with Article 27 of trips, which designates patentable subjects matter as that which 
is new, involve an inventive step and is capable of industrial application. It may, 
however, be argued, from the other side64, that the utility requirements in terms 
of South African law, is broader than the “industrial application” in the TRIPS 
Agreement since it includes trade and agriculture alongside industry. Therefore, it 
seems as though section 25 (9) of the Patent Act allows for the patenting of new 
uses of known substances: 
“The fact that the substance or composition forms part of the state of the art 
immediately before the priority date of the invention shall not prevent a patent be-
ing granted for the invention of the substance or composition in any such method 
does not form part of the state of the art at that date.”
55 See generally Oh, ‘Domestic Legislation and Court Decisions on Intellectual Pro-
perty Rights and Public Health in South Africa’ 1- 11 at http://www.docstoc.com/search/
south-africa/3 last accessed 16/12/2019.
56 Constitution of the Republic of South Africa.
57 Act 57 of 1978.
58 Patent Laws Amendment of 1997.
59 Act 20 of 2005.
60 Act 101 of 1965.
61 Act 90 of 1997.
62 Act 59 of 2002.
63 Act 89 of 1998.
64 Supra at (note 53) at 2.
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The above-cited provision goes beyond the requirement of trips because in 
it there is no specific reference to the patenting of new uses of known substances. 
It is, therefore, a weakness in the law which likely to encourage evergreen patents 
and hinder affordable access to medicines.65 A countermeasure to this, with regards 
to the access to drugs is section 56 (2) (d)66 which enables the use of compulsory 
licences to tackle unjustifiably expensive medicines and improve availability. Com-
pulsory licenses are allowed where patent rights are abused67, and where such abuse 
occurs, any interested person may apply for a license. The matter of government 
use of patents is related to the compulsory licenses subject.68 With this respect, 
from the perspective of access to medicines, the relevant section of the Patent Act 
is generally understood to empower the Minister to issue compulsory licenses for 
public purposes, including ensuring access to a sustainable supply of affordable 
medicines. The domestic provision is not explicit in its reference to “national 
emergency or other circumstances of extreme urgency” or “to cases of public non-
commercial use” as the trips Agreement eloquently describes it. However, the 
wording in section 4, which authorizes the use of the patented invention by the 
government in the public interest, without the aquiescence of the patent holder, 
is coherent with the corresponding provision of the trips Agreement.69
Medicines and Substances Control Amendment Act
The Medicines and Substance Control Amendment Act70 is now the focus of our 
attention. This Act was passed with the intention of clarifying the legal standing 
of parallel imports of Pharmaceutical products. The Act adopts the international 
exhaustion of patent rights and enables the Health Minister to establish the 
procedure and the conditions for a patented medicine, to be imported in paral-
lel, once it is in the market.71 This sparked a lot of controversies and resulted in 
acrimonious litigation against the government by big pharmaceutical companies. 
The cases are discussed below.
Pharmaceutical Manufacturers Association of South Africa v  
President of the Republic of South Africa72
Unfortunately, medicine to combat hiv is costly. Often the patented or ‘designer’ 
forms of these drugs can cost between $15, 000 to $20,000 per year in the United 
65 Supra Ndlovu (note 6).
66 Section 56 (2) the Patent Act of 1978.
67 Section 56 (1) of the Act.
68 Section 4 of the Act provides for government use of patents through the relevant Minister.
69 Oh at (note 57).
70 Act 90 of 1997.
71 Section 15 (c) of the Act.
72 Pharmaceutical Manufacturers Association of South Africa v President of the Re-
public of South Africa, case No. 4183/98.
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States; comparatively, per capita income in South Africa is only $6, 800.73 This 
means that developing countries are facing the HIV epidemic without the na-
tional income means to combat this growing problem.74 Some governments have 
responded to the urgent issue by importing much cheaper generic hiv medicines 
for an approximate cost of $350 per annual treatment.75 The South African 
government enacted the Medicines and Related Substances Act of 1997 and its 
subsequent Medicines and Related Substances Amendment Act of 2003, in order 
to grant the South African Minister of Health the power to ‘prescribe conditions 
for the supply of more medicines in certain circumstances as to protect the health 
of the public’, as a mitigation measure for the growing emergency.76 The amend-
ment contained section 15C which deals with measures to ensure a supply of 
more affordable medicines by allowing parallel importation of medicines and the 
issuance of compulsory licences under specific conditions. It must be highlighted 
that even before it came into force, the Act was criticized by the international 
pharmaceutical industry, the United States and the European Union77 at a time 
when South Africans were dying by the hundreds. 
In February 1998, 42 applicants (big pharmaceutical companies) presented a 
lawsuit against the South African government. The applicants claimed that South 
Africa violated the trips Agreement and section 25 of the Constitution when the 
country changed its law. It was argued that the challenged legislation violated Ar-
ticle 27 of trips78 as it allegedly discriminated patent owners in the pharmaceutical 
field.79 The office of the us Trade Representative (ustr) entered into the fray and 
tried to influence the outcome by listing South Africa in its annual hall of shame, 
the special 301 list.80 The South African government, on the other hand, argued 
that under its Constitution,81 it is ‘obliged’ to protect its citizen’s right to health. At 
the meeting in 2001, all the World Trade Organization members agreed (includ-
ing the United States) that public health concerns should override certain patent 
73 D. Reekie, South Africa’s Battle with aids and Drug Prices, at http://www.org/
ba334/ba334.html last accessed 13/12/2019.
74 Trade and Development in the World Trade Organization, at http://www.wto/
english/trutop_e/devel_e.htm last accessed 13/12/2019.
75 M. Leis, Death by Treaty: South Africa’s Medicines and Related Substances Amend-
ment Act of 1997 andthe Agreement on Trade Related Aspects of Intellectual Property 
Rights. Journal of International Business and Law Vol. 3 Issue 1 (2004). Available at 
https://scholarlycommons.law.hofstra.edu/cgi/viewcontent.cgi?article=1034&context=jibl 
. See also Pressure Against Drug Companies Blackmailing Africa (2001) at http//www.
afrol.com/categories/health/health_aidsdrug_price.html 
76 Section 15C of the Medicines Amendment Act of 1997.
77 R. L Ostergaard, ‘The Political Economy of the South African- United States 
Patent Dispute’ The Journal of World Intellectual Property (2000) at 880.
78 Ibid.
79 The US government justified South Africa’s placement on the list on the basis 
that the Act gave the Minister ill- defined authority to authorize parallel imports, issue 
compelling licenses, potentially otherwise abrogate property rights.
80 Ostergaard (note 79) at 883. See also Ndlovi (note 6).
81 Section 27 of the Constitution.
20     .º 30 -  ju -cb  2020 -  .  5  -  47
Luz Helena Hanauer and Isaac Quinton Ramaphala
rights.82 Treatment Action Campaign (tac), a South African Non-Governmental 
Organization representing people with hiv, joined the case as amicus curiae. 
Shortly thereafter, 300 000 individuals and 140 groups across 130 countries signed 
a petition demanding the withdrawal of the case against the government, which 
had lots of sympathy from the tac and like-minded organisations.83 The pressure 
was strong for pharmaceutical companies which had launched the lawsuit. In fact, 
after the United Nations general secretary undertook substantial mediation efforts, 
the pharmaceutical companies withdrew the suit. Furthermore, the South African 
and us government reached an agreement that led to the removal of South Africa 
from the ustr 301 list.84
That case put the trips Agreement and access to medicines on the international 
agenda, and it remained there due to increasing awareness about hiv/aids.85 It 
was important as it raised consciousness about access issues to medicines from the 
developing countries’ perspectives and unmasked a greedy and unethical dimension 
of the Pharmaceutical industry which actively attempted to curtail South Africa’s 
rights under the trips tackling parallel imports and compulsory licenses. 
Minister of Health v New Clicks South Africa86
The Medicines Act was first enacted in South Africa in 1965. It has been amended 
at least fifteen times from 1965 until 1997 and the main focus of the Act was quality 
control.87 In 1997, a number of measures were implemented with the intention of 
increasing affordability of medicines nationally as outlined above. Yet, the newly 
introduced measures, especially those contained in section 15A- C, sections 18A- C 
and sections 22B- H, do not fit comfortably into an Act designed to serve other 
purposes.88 They presented new problems for those who had to apply them. The 
grafted sections make provision for controls to be introduced with respect of the 
production, importation, distribution and sales of medicines,89 the relaxation of 
certain patent restrictions, the promotion where possible, of generic substitution 
of medicines, and the establishment of a Pricing Committee. Such a committee is 
82 Though the implementation of this decision is not pursued in practice.
83 M. Heywood, ‘Debunking “Conglo-Talk”: A Case study of the amicus curiae as an 
instrument for advocacy, investigation and mobilisation’ Law, Democracy, Development 
5 (2) (2001) 133 139- 144.
84 Ibid at 156.
85 This case has led to South Africa, Thailand and Brazil to be put on the ustr 301 
watch list for being trips compliant.
86 Minister of Health v New Clicks South Africa (Pty) Ltd 2006 (2) SA 311 (cc) 
Available at https://www.globalhealthrights.org/wp-content/uploads/2013/01/CC-2005-Mi-
nister-of-Health-and-Anr.-v.-New-Clicks-South-Africa-Pty-Ltd.-and-Ors..pdf 
87 See in this the remarks of Kriegler aja in Administrator, Cape v Raats v Rontogen 
Vermeulen (Pty) Ltd 1992 (1) 245 (A) at 254b-e.
88 New Clicks (note 88) para 2.
89 The Medicines Act.
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tasked with making recommendations for the introduction of a pricing regulation 
for all pharmaceutical drugs sold in the Republic.90
The new measures evidently invited strong opposition from within the 
pharmaceutical industry, including litigation challenging the validity of certain 
provisions of the amending legislation. In May 2004, the High Court received 
two applications challenging the regulations. The challenges attacked the func-
tioning of the Pricing Committee, the procedures used by the Pricing Committee 
and the substance of the regulations promulgated by the Minister on the Pricing 
Committee’s recommendation. The Pricing Committee decided to abide by the 
decision of the High Court. The majority dismissed the challenges to the regula-
tions while a minority judgement held that the regulations should be set aside on 
various grounds.91 The applicant sought leave to appeal against the order of the 
High Court, and the application for leave to appeal was by agreement heard in the 
High Court on 20 September 2004. Judgement was reserved. As there was a delay 
in delivering the judgement on the application for leave to appeal, for this reason 
the Pharmaceuticals decided to approach the Supreme Court of Appeal seeking 
a leave for appeal.92 The matter was heard. The High Court, on the other hand, 
delivered the reserved judgement where the majority opinion denied the leave to 
appeal,93 before the sca handed its judgement. Ultimately, on December 20, 2004 
the sca handed down a unanimous judgement affirming its jurisdiction to hear 
the matter, granting leave to appeal and holding the regulations to be invalid.94 
The Minister and the Pricing Committee then applied for leave to appeal to the 
Constitutional Court against the sca’s decision.
One of the contested provisions brought before the Court was section 22G 
of the Medicines Act. The Pricing Regulation, promulgated under this provi-
sion, apply to the sale of medicines privately (sales to the state occur through 
a tender process). The manufacturer or the importer (referred to collectively as 
manufacturer) was required to set the single exit price (sep) of each medicine 
upon the commencement of the Pricing Regulations in May 2004. Chaskalson 
CJ95 envisaged that the sep is the only price at which the manufacturer may sell 
medicines to persons other than the state and that distributors, wholesalers, and 
pharmacists may not sell medicines at a price higher than the sep. The sep consists 
of the ex-manufacturer price of the medicine, the logistics fee (the fee paid to the 
90 New Clicks (note 88) para 2.
91 New Clicks South Africa (Pty) Ltd v Tshabala-Msimang and Another nno; Phar-
maceutical Society of South Africa and Others v Minister of Health and Others 2005 
(2) sa 530 (cc).
92 New Clicks para 84.
93 New Clicks South Africa (Pty) Ltd v Tshabala-Msimang and Another nno; New 
Clicks South Africa (Pty) Ltd v Minister of Health and Another 2005 (3) SA 231 (C).
94 New Clicks South Africa (Pty) Ltd v Tshabala-Msimang and Another nno; New 
Clicks South Africa (Pty) Ltd v Minister of Health and Another 2005 (SA) 238 (sca); 
2005 (6) bclr 576 (sca).
95 New Clicks at (note 88) per Chaskalson CJ para 224.
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distributors or wholesalers of medicine), and value-added tax.96 For the first year 
of implementation, the Pricing Regulations provided a formula determining the 
maximum sep that was to be set by the manufacturers, considering the price at 
which the medicine was sold and the discounts offered in 2003, and where neces-
sary, the price of the medicine in other countries.97 
The formula was an attempt to determine the lowest fair price for the medicine 
considering what manufacturers actually need to cover their costs and what they 
charge for the medicine both in South Africa and in other countries. Once the 
sep is set, it may be increased annually using Regulation 7 (if there has been no 
Ministerial determination of the maximum price increase) or it may be increased 
quarterly using Regulation 8 (3) (if there has been a Ministerial determination of 
the maximum increase).98 The provision is made for the setting of a maximum 
logistics fee to be charged by wholesalers or distributors and for a maximum 
dispensing fee to be charged by retailers. In this way, the Pricing Regulations to 
introduce transparency of pricing into most levels of the supply chain. For our 
purpose, the Constitutional Court held that the purpose of section 22G and the 
Pricing Regulation was ‘to promote the availability of safe and effective drugs at the 
lowest possible prices.’99 The mischief, therefore, to which section 22G is directed 
is the lowering of the high costs of drugs. It is within this context that the Court 
held unanimously that the challenge to the regulations “overall” must fail and that 
the Supreme Court of Appeal was accordingly wrong in setting aside regulations as 
a whole. However, unlike the High Court judgement, it considered a wide range 
of challenges to individual regulations where severance of certain words/ reading 
in of other words cured defects in the regulations.
Competition Act
In terms of Article 31 (K) of the trips Agreement, patents may be overridden 
and compulsory licenses issued if it is proven that the right holder is involved in 
anti-competitive behaviour, such as abusing a dominant position in a market by 
charging excessively high prices for pharmaceuticals.100 The Competition Act is also 
relevant in the matrix of pharmaceutical price regulation as patented medicines are 
effectively granted a legal monopoly for the duration of the patent. Companies that 
hold the patent are therefore likely to be dominant in the market for the particular 
medicine. The Competition Act seems to remain applicable in this situation and 
provides, inter alia, that a dominant firm is prohibited from charging an excessive 
96 Ibid para 263.
97 Ibid para 276.
98 Ibid.
99 New Clicks para 231 as per Chaskalson CJ.
100 Article 31 (K) of trips.
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price to the detriment of consumers, and from refusing to give a competitor access 
to an essential facility.101 
It is arguable that a firm that holds a patent might be found to be abusing its 
dominant position and may inter alia be ordered to stop charging excessively102 
or to grant a competitor access to its patented knowledge by way of compulsory 
license.103 There is some overlap between the powers of the Commissioner of 
Patents and the Competition Tribunal as an abuse of patent rights, and an abuse 
of a dominant position might arise from the same set of facts. South Africa used 
competition law to reduce anti-competition practices, but a compulsory license 
was never issued, as illustrated briefly below.
Hazel Tau and Others vs. GlaxoSmithKline SA (Pty) Ltd and Others
The Treatment Action Campaign (tac) filed a complaint at the Competition 
Commission against GlaxoSmithKline (gsk) and Boehringer Ingelheim (bi) on 
behalf of 11 patients and medical professionals in September 2002. The com-
plaint raised the allegation that those companies allegedly engaged in excessive 
pricing of arvs, to the disadvantage of consumers, and such a form of behaviour 
was prohibited by section 8 (a) of the Competition Act. The complainant further 
alleged that the excessive pricing of arvs was directly responsible for premature, 
predictable, and avoidable deaths of people living with hiv/aids, including both 
children and adults.104
The complainants asked the Commission to interrogate and refer the matter 
to the Competition Tribunal for relief contemplated by section 8 of the Act, in 
the form of an Order against gsk and bi ordering them to stop their excessive 
prices practice; a declaration that gsk and bi conducts constituted a prohibitive 
practice; and further, a fine up to 10% of their annual South African turnover.105 
The Competition Commission referred the case to the tribunal maintaining that 
gsk and bi were in contravention of the Competition regulations because they 
were refusing to license their patents to generic manufacturers for a reasonable 
royalty, (gsk and BI only had a licensing agreement with a single generic producer-
Aspen Pharmacare - on royalty terms of 30% and 15%).106 The Commission held 
that the defendants contravened sections 8 (a) (d), in that, they had abused their 
dominant positions in the market by charging excessive pricing to the detriment 
101 Section 8 (a) (b) of the Competition Act.
102 See Genzyme Ltd v Office of Fair Trade [2004] cat, Napp Pharmaceutical Holdings 
Ltd v Director General of Fair Trading [2002] cat 1.
103 See: ims Health GmbH & Co KG v ndc Health GmBH Co kg ecr 2004 p I- 
05039, the European Commission of Microsoft, case no 37.792.
104 See para 107 of the statement complaint , available at http://www.tac.org.za/
Documents/DrugCompaniesCC/HazelTauAndOthersVGlaxoSmithKlineAndOthersState-
mentOfComplaint.doc last visited (17/12/2019).
105 Supra (note 53).
106 Ibid.
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of consumers and impeding the access of a competitor to an essential facility thus 
engaging in an exclusionary act.
In addition to the above described findings, the Commission also stated that 
it would ask the Tribunal to make an order authorizing the making of generic 
versions of the drugs in question.107 The case did not proceed to be heard on its 
merits since, in December 2003, gsk and bi conceded to settlement which saw 
the two companies agreeing to allow select generic companies to manufacture and 
sell some of their antiretroviral drugs in sub- Saharan Africa in return for a royalty 
not exceeding 5% of net sales of the relevant antiretroviral drugs.108 This was a 
significant access victory to medicines, and for the first time, generic versions of 
patented drugs were to be commercially available in South Africa.109
The Draft Intellectual Property Policy
The Draft Intellectual Property Policy has recognized the weaknesses in the South 
African ip law generally and patent law, in particular.110 Some of the provisions of 
the policy which are likely to have a positive impact on access to medicines are the 
ones described in the sections “forms of ip”;111 “ip and Public Health;”112 “ip and 
indigenous knowledge”;113 “ip, Competition, Public Policymaking, compulsory 
licensing and technology transfers”;114 “patent reform”;115 “enforcement of ip”;116 
and “overall recommendations.”117
Several provisions in the draft ip policy are likely to impact directly or indirectly 
on access to medicines.118 However, only the areas of patents and public health 
provisions outlined in chapter 1 of the draft policy shall be examined as it contains 
the policy119 on the subject of this paper120 . Despite the fact that the definition 
of patents in chapter 1 is rather simplistic (‘a patent is associated with technology 
transfer, public health and substantive examination),121 the policy makes com-
107 Ndlovu at (note 6) at 221.
108 Ibid at 222.
109 Ibid.
110 See Department of Trade and Industry South Africa, “Draft National Policy on 
Intellectual Property 2013: Invitation for the Public to Comment on the National Policy 
on Intellectual Property 2013 (Notice 918 of 2013)”, published in Government Gazette 
no. 36816 on 4 September 2013 (hereafter Draft IP Policy), available at www.gov.za/
documents/download.php?f=198116 last accessed on 12/12/2019.
111 Draft ip Policy at 8- 20.
112 Ibid at 21- 22.
113 Draft ip Policy at 23.
114 Ibid at 23- 29.
115 Ibid at 31.
116 Ibid at 42- 44.
117 Draft ip Policy at 44.
118 The following Chapters of the Policy are gratingly relevant in this context: chapter 
1, 2, 4, 7, 8, 9 and 10.
119 At 8- 14.
120 The ‘spirit and purport’ of the policy are captured succinctly in the objectives of 
the policy, outlined at page 4 of the policy document.
121 See Chapter 1 (a) of the policy document at 8.
 25    .º 30 -  ju -cb  2020 -  .  5  -  47
ip regulation in south africa – evolution, current status,  
and comparison with sadc region countries
mendable recommendations that a substantive search and examination process 
be followed in South Africa.122 It is important to note that South African patent 
law employs a non-examination or depository system. Although section 34 of 
the Act123 requires the registrar to examine every application to see if it complies 
with the requirements of the Act- which means also section 25 (1) which sets out 
substantive requirements of a valid patent- this section is qualified that the exam-
iner ‘shall examine in the prescribed manner.’ Unfortunately, regulation 41 of the 
Patent Regulations124 merely empowers the registrar to rule on the compliance of 
the formal requirements of the patent application. Therefore, South Africa has no 
novelty examination. The moving from a depository to a substantive examination 
system of patent applications is vital and central to ensuring that only valid and 
strong patents are granted in the future.
Other countries such as Brazil, India, and Egypt have introduced a substantive 
examination system, and are consequently granting few patents than they did be-
fore.125 This paper goes on to acknowledge that, especially with regard to patents in 
the area of medicines, the granting of weak patents stifles the possibility of having 
access to public health. The author states, ‘South Africa uses a registration system 
that is not per se able to scientifically critique newness, obviousness, novelty, and 
usefulness in trade or agriculture. Due to this, weaker patents are granted.’126 A 2011 
study by the University of Pretoria showed that more than 80% of the applications 
at cipro would not have been granted under an examination system.127 Many have 
voiced their resignation to introducing a substantive examination system, as it is 
not feasible in South Africa. With an examination system comes the need to hire 
examiners who possess the required skill and specific knowledge in one or more 
disciplines. Examiners need to understand the procedural, technological, and legal 
aspects of patent examinations.128 Thus, education and training of employees in 
the said technical fields would be necessary, which takes both time and money.
Countries such as Turkey have found a way around this dilemma. The Turkish 
Patent Office sends their patents to Russian, Swedish or European Patent Offices 
for the substantive examinations.129 Therefore, there is always a possibility of di-
verting the substantive examinations of patent applications either entirely or just 
temporarily until enough examiners have been trained to enhance their searching 
122 At 10 -11.
123 Patent Act of 1978 (as amended).
124 Ibid.
125 R. Davies, ‘Draft National Policy on Intellectual Property’, Department of Tra-
de and Industry 918 (2013) 14 Available at http://blogs.sun.ac.za/iplaw/files/2013/09/
gg36816_nn918.pdf 
126 Ibid 13- 14.
127 A. Pouris & A. Pouris, ‘Patents and economic development in South Africa: 
Managing Intellectual Property Rights, sajs 5 107 11-12.
128 Chair of Intellectual Property ‘Commentary pm Draft national policy on Inte-
llectual Policy’ (2013) 3-6.
129 S. Busch, ‘Promoting Access to Affordable Generics: Reforming South Africa’s 
Patent Law to Prevent Evergreening’, iplj 101 (2016).
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and examining capabilities.130 The mere excuse that the introduction of a sub-
stantive examination system would require training of examiners cannot be used 
as a reason to continue with the current patent regime, which is granting weak 
patents and is being taken advantage of by pharmaceutical companies by means 
of evergreening. The introduction of a substantive examination system is the first 
step in the correct direction towards promoting access to affordable generics and 
granting fewer ‘weak’ patents.
The policy recognizes the country’s public health problematic and finally 
articulates that South Africa as developing member wto, is in the position of 
taking advantage of the flexibilities offered by the trips Agreement to access 
to medicines.131 The policy recommends that South Africa amend its patent 
laws to incorporate trips flexibilities and reflect public-health exceptions to 
patentability.132On data protection, it has been said elsewhere133 that the trips 
Agreement provides for data protection against unfair commercial use but does 
not provide for data exclusivity.134 The existence of this exception, which allows 
members to permit generic medicines manufacturers to undertake and complete 
their talk of obtaining regulatory approval from national regulatory authorities 
from generic revisions before original patents expire, was confirmed by the wto 
in a panel ruling involving Canada and the European Union.135 The policy 
notes with concern the behaviour of some multinational pharmaceutical com-
panies which lobby their governments to put pressure on developing countries 
to introduce laws that protect data exclusivity.136 This kind of action does not 
augur well for access to medicines since it will, in all likelihood, delay the entry 
for generics into the local market since generic companies would not be able to 
conduct research and experiments before the patent expires. The policy urges 
South Africa to continue protecting data in terms of trips prescripts137 but not 
to allow data exclusivity.
The policy also comments and makes an incisive recommendation on two new 
items that are administrative rather than pure ip issues. The first is the harmoni-
zation of the database of the former Medicines Control Council (mcc) and the 
Companies and Intellectual Property Commission (cipc).138 While it is good that 
130 Ibid at 115.
131 See para 1 (a) (iii) of the policy at 9.
132 Chapter 1 paragraph (iii) of the policy and the accompanying recommendations. 
133 Ibid.
134 Article 39 of trips Agreement.
135 See wto Panel Report on Canada – Patent Protection of Pharmaceutical Pro-
ducts wt/ds114/r 17 March 2000 available at http://www.wto.org/english/tratop_e/
dispu_e/7428d.pdf 
136 Para 1 (a) (iii) at 10.
137 In terms of the relevant provisions of the Patent Act, section 69A provides for 
data protection.
138 Para 1 (a) (ix) at 11. It must be noted that currently the Medicines Control Council 
has been converted into the South African Health Products Regulatory Authority (sah-
pra) and to date the databases have not been merged as the mandate to sahpra is more 
comprehensive including naturopath products, homeopathic products and supplements. 
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the two-related government departments share information and access each other’s’ 
database, it needs to be done in a convenient way that does not creates unnecessary 
delays for the introduction of new medical products on the market.139 With the 
restructuring of the former mcc into the South African Health Products Authority 
(sahpra), this recommendation seems difficult to be enforced at the moment. The 
second issue is referred to whether or not applicants for pharmaceutical patents 
should be ‘rewarded/ appeased’ for the delay in their approval of their medicines 
by granting them an extension to the 20 years patent term.140 While patent exten-
sions may be interpreted as trips-plus, it is still not per se illegal since the trips 
Agreement sets 20 years as the minimum period.141 This is the reincarnation of 
sections 50, 51 of the first South African Patent Act, accompanied by sections 3 
(1) of the 1978 Act mentioned in the apartheid section. Critics of the pharma-
ceutical industry acknowledge that most pharmaceuticals are only profitable for 
approximately 10 years, as contrasted with twenty years monopoly granted by most 
patent systems.142 This means that for half of the patent’s life it acts as a deterrent 
rather than a reward for time and money invested. Upon going it can be argued 
that the second 10 years period for pharmaceutical patents acts only to prevent 
generic, low, cost equivalents depriving those in need of affordable medicines.143 
Therefore, the patent extension has the effect of delaying the entry into the South 
African market and for this reason it should be discouraged.
Finally, the Draft Policy should be commended for coming up with an im-
portant provision dealing with ‘alternatives to ip.’144 In terms of the draft, two 
alternative mechanisms for promoting innovation are ‘subsidy’ and the ‘prize’.145 
The subsidy requires a direct or indirect public investment to the innovator for 
pursuing inventions. The risk of loss in this instance is to be shared by the govern-
ment and the innovator. This approach is widely used by the US government in 
sensitive areas such as military technologies and the development of vaccines to 
address bioweapon threats.146 The subsidy approach can be seen in South Africa 
government through the National Research Fund (nrf ) system, for example, to 
train more scientists achieving doctoral and postdoctoral qualifications and to 
bridge the skills gaps present in certain industries. The subsidy approach is rarely 
targeted at obtaining patents. One example of this is The Bill & Melinda Gates 
139 Ndlovu (n 6) at 212.
140 Para 1 (a) (x) at 11.
141 See Article 33 of trips.
142 K. Bombach, ‘Can South Africa really fight Aids? Reconciling the South African 
Medicines and Related Substances Act with the trips Agreement’, intl 19 B.U L7 273, 281.
143 Ibid at 302.
144 See Ndlovu (n 6). See also Chapter 1 paragraph 7 and accompanying recom-
mendations at 19.
145 Ibid.
146 See Bombach, (n144) at 283.
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Foundation, that has provided a significant amount of money for global health 
projects.147
According to the Foundation, many of the research grants are paid upfront, 
before a viable product is developed. A review process is in place to verify that 
there is progress towards the desired goal.148 Unfortunately, the vast majority of the 
Foundation’s initial projects were unsuccessful, and it had altered its project fund-
ing strategy as a result. Therefore, targeting obtaining a patent is very difficult, and 
the government seeks to lose a lot of money if it is to invest in such programmes, 
though it is important to acknowledge that such subsidies are allowed in terms of 
wto Agreement as non-actionable r/d subsidies.149 The ‘prize’ approach entails the 
provision of a previous funding award towards a target that innovators are invited 
to achieve. The logic behind this is that innovators will be incentivized to by prize 
will expand his or her own resources to achieve the pre-determined goal. Whether 
this approach encourages innovation is not yet verified, however, the draft policy 
recommends to explore it too.150
One should note that most aspects of the policy not outlined in this section 
will be carefully examined in the next section when doing a comparative analy-
sis of patent laws in Africa and their cases of universal healthcare. In summing 
up South Africa’s Draft ip Policy, the document is solid in the pursuit of a just 
outcome, although it does not in any way refer to exceptions to patents based on 
research, experimentation, and educational purposes.151 Should the public health 
provisions of the current Patents Act be amended in a to incorporate the policy 
proposals, the legal structure would be enhanced, coverage and access would be 
improved, and all this will definitely impact positively the access to medicines 
in South Africa.
147 D.C. McNell, Five Years In, Gauging Impact of Grants, ny Times, December 
20, 2010.
148 Ibid.
149 The relevant wto Agreement dealing with subsidies is the Agreement on Subsidies 
and Countervailing Measures (scm Agreement), available at http://www.wto.org/english/
docs_e/legal_e/24-scm.pdf (last visited 19/11/2013). In terms of Article 3 of the scm 
Agreement, two categories of subsidies are prohibited, namely export and local content 
subsidies. Export subsidies are subsidies contingent, in law or in fact, whether wholly or 
as one of several conditions, on export performance. On the other hand, local content 
subsidies are contingent, whether solely or as one of several other conditions, upon the 
use of domestic over imported goods. These two categories of subsidies are prohibited 
because they are designed to directly affect trade and thus are most likely to have ad-
verse effects on the interests of other Members. Therefore, subsidies to spur innovation 
and boost patents will not be prohibited as long as they are applied in adherence to the 
national treatment and the most favoured nation principles. 
150 Page 19 of the Draft ip Policy.
151 Indian Patent law allows for educational and research exceptions.
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4. brief comparison with other cases of universal healthcare
India
Case Law
Novartis AG v Union of India152
On April 1, 2013, the Indian Supreme Court delivered what is described as a 
significant judgement in an appeal brought to it by Novartis, Swiss-based phar-
maceutical company with a business presence in India, against the rejection by the 
India Patent Office of a product patent application for a specific compound, the 
beta crystalline form of Imatinib Mesylate.153 The legal issue at stake was whether 
or not the appellant was entitled to a patent for the beta crystalline form of the 
compound Imatinib Mesylate, which is a therapeutic drug for chronic myeloid 
leukaemia and certain kinds of tumours and is marketed under the name “Glivec 
or Gleevec.”154
The drug Glivec, manufactured by Novartis Pharmaceuticals, was initially 
invented by Jurg Zimmerman, a medical chemist, who invented a number of 
derivatives of N- phenyl- z- pyrimidineamine.155 The name Imatinib was given 
to one of the derivatives as a non- proprietary name by the World Health Orga-
nization.156 The derivatives, including Imatinib, are capable of inhibiting certain 
protein enzymes and have valuable anti-cancer properties, which makes them suit-
able for the treatment of warm-blooded animals.157 Imatinib and other derivatives 
were submitted to the United States Patent Office for the registration of a patent 
therein on April 28, 1994 and the patent sought was granted in 1996. Further 
research revealed that the beta crystalline form of Imatinib is more stable, Novartis 
sought to patent this in the us, and after initial opposition from the Patent Office, 
a patent was granted in the us.158 Novartis also applied for a patent in India for 
the same product in 1998, but the application was considered only in 2005 when 
India became truly compliant with the trips Agreement.159
152 Ndlovu, L. Lessons for the sadc from the Indian case of Novartis ag v Union 
of India. per [online]. 2015, vol.18, n.4 [cited 2020-10-11], pp.783-815. Available at: 
http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S1727-37812015000400003&ln
g=en&nrm=iso . See alsoNovartis ag (Supreme Court of India) Civil Appeal n.º 2706-
2716 on 1 April 2013.
153 Abbot, Intellectual Property Watch (2013).
154 Novartis para 195. The test for invention and patentability are provided for in 
s 2 (1) (j)- (ja) and s 3 (d) of the Patent Act. See also Lessons for the sadc from the 
Indian case of Novartis AG v .... http://www.scielo.org.za/scielo.php?script=sci_arttext&
pid=S1727-37812015000400003
155 Novartis (n154) para 3.
156 Ibid. para 5. For context, see also: https://lawsofland.blogspot.com/2018/ 
157 Ibid.
158 The patent was granted under us Patent number 5 521 184.
159 From 1 January 2005, India allowed drug patents application in order to comply 
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The important developments occurred before the patent application was 
considered by the Chennai Patents Office. Firstly, the Patent Act was amended 
and section 3 (d)160 was introduced. Section 3 (d) excludes from patentability: 
“the mere discovery of a new form of a known substance which does not result 
in the enhancement of the known efficacy of that substance or of the mere use of 
a known process, machine or apparatus unless such a known process results in a 
new product or employs at least some new reactant.”
Secondly, before the patent application was considered, it had attracted five 
pre-grant applications.161 Pre-grant application is provided in section 25 of the 
Patents Act of 1970 as amended. The most vocal oppositions came from rival 
pharmaceutical companies and patent groups, bearing their opposition mainly on 
the fact that it was obvious that the illegal invention had been anticipated, and 
ran afoul of section 3 (d) of the Patent Act. The Court purported that the object 
of section 3 (d) sought to achieve was to prevent evergreening, provide easy ac-
cess to life-saving drugs to citizens, and realise the constitutional obligations to 
provide health care to citizens.162 The Court clarified the legal provisions as fol-
lows: ‘the 1970 Patent Act as amended in 2005 requires that an invention must 
be new (not anticipated), involve an inventive step,163 and be capable of being 
made or used in an industry.164 The requirement that an invention must involve 
an inventive step implies that there must be a feature that involves a technical 
advance as compared to existing knowledge or having economic significance or 
both. Furthermore, this feature should be such that the invention is not obvious 
to a person skilled in the art.’
It was submitted on behalf of Novartis that section 3 (d) was not an exception 
to patentability. Hence, once a substance satisfies the requirements in section 
2 (1) (j) and (ja), it satisfies the requirements of patentability. Consequently, 
section 3 (d) did not apply to the Novartis case.165 This submission was made 
notwithstanding the concession by Counsel for Novartis that the aim of section 
3 (d) was to prevent small change and evergreening while allowing and encourag-
ing incremental patentability.166 With specific reference to public health and the 
use of TRIPS flexibilities, Novartis argued that the best route was to make use of 
with the requirements under trips. See specifically, Chaudiri, ‘Economic and Political 
Weekly’ 46 2011.
160 S 3(d) excludes from patentability “the mere discovery of a new form of a known 
substance which does not result in the enhancement of the known efficacy of that substance 
or of the mere use of a known process, machine or apparatus unless such known process 
results in a new product or employs at least one new reactant” (emphasis out of text). 
161 Pre-grant oppositions are provided in s 25 of the Patents Act of 1970 as amended.
162 The Supreme Court at para 18 cited with the approval which was spelled out by 
the Madras High Court in earlier litigation in the matter.
163 Ibid para 88- 89.
164 S 2 (1) (j) (i) – (iii) of the Indian Patent Act.
165 Novartis (n154) para 99.
166 Ibid. para 100.
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compulsory licenses, 167 revocation proceedings168 and multiple stages of patent 
opposition procedures169 rather than to make the case of section 3 (d).170 It was 
also argued on behalf of Novartis that the production of Imatinib Mesylate from 
Imatinib in a free base was a result of a step involving a technical advance when 
compared to current knowledge, thus bringing into existence a new substance.171
The Supreme Court rejected this argument and ruled that the production of 
Imatinib Mesylate did not constitute an invention as contemplated in the current 
law of India.172 In dismissing the submission, the Court remarked thus: 
‘We firmly reject the appellant’s case that Imatinib Mesylate is a new product 
and the outcome of an invention beyond the Zimmerman patent.’173
Therefore, the specific product did not satisfy the test of an “invention” as 
laid down in sections 2 (1) (j) (ja) of the Patents Act.174 The court dismissed the 
submission with the compelling observation that the beta crystalline form of Ima-
tinib Mesylate is a new form of a known substance, namely, Imatinib Mesylate, 
with a well- known efficacy.175 Therefore, the fact that the beta form of Imatinib 
was a product that claimed to enhance the form of its old counterpart triggered 
the application of section 3 (d).
A Comparative Analysis between India and South Africa
The Draft ip Policy policies which have not been mentioned in the section above 
will now be examined in comparison with the patent laws of India. This will be 
complemented with the interview of the Minister of Health’s interview at a time, 
Dr Motsoaledi’s response to the leaked Public Affairs Engagement (pae) strategy 
by pharmaceutical companies. The pae strategy document entitled ‘A Proposal 
Prepared for Phrma and ipasa: Campaign to prevent Damage to Innovation from 
the Proposed Draft National ip Policy in South Africa’ outline ipasa’s phased out 
plan for countering the Draft National Policy. On 8 April 2014, Dr Motsoaledi 
was interviewed by Tembisa Morele on Interface, a political talk show, loosely 
modelled on the bbc’s Hard Talk, which is aired by the South African Broadcasting 
Corporation Channel 3 (sabc 3).176 The video is available online.177 The interview 
167 In terms of Chapter xvi of the Patent Act.
168 As provided for in s 63, 64 and 65 of the Patent Act.
169 In terms of s 25 of the Act.






176 For a view on the initial aspirations for the show, see The Media online ‘Mckaiser: 
Why I resigned from sabc’s Interface’, available at http://themediaonline.co.za/2011/07/
mckaiser-why-iresigned-
from-sabcs-interface/ last accessed 09/12/2019
177 sabc digital News ‘YouTube Channel’: available at http://www.youtube.com/
watch?v=cnzattvbdc (last accessed 10/12/2019).
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is important because, in the absence of a written response by the government to 
the pae strategy, it provides a comprehensive response on the government’s behalf 
by the Ministry of Health.
New Use Patents
The Indian case discussed above was mainly a complaint about Novartis’ effort 
to register a patent in India for a compound that was already state of the art and 
therefore not necessarily a candidate for registration as a patent. It is important to 
note that that the patent which Novartis sought to register in India was initially 
rejected by the us patent authorities for lack of novelty and granted only on ap-
peal in May 2008.178 A significant number of African countries, including South 
Africa, allow patents for new uses of known medicines, mostly through legislation 
that allows for the grants of patents generally without an express reference to the 
prohibition of new uses of known substances.179
The problem is well illustrated in South Africa. Section 25 (a) of the South 
Africa’s Patent Act of 1978, provides for the patentability for such new uses with-
out any further qualification or conditions. According to the Treatment Action 
Campaign (tac), Novartis managed to register in South Africa a patent for a “new 
use” of Imatinib which does not expire until 2022, even though the original patent 
was set to expire earlier in 2017.180 To treat chronic myeloid leukaemia for one 
year in South Africa using Novartis Imatinib costs R387,000, a price out of reach 
for most South Africans and medical aid schemes.181 The stack irony is that what 
Novartis lost in the Supreme Court of India, was gained in South Africa through 
registration of a secondary new use form of Imatinib.
It is noteworthy to point out that Pharmaceutical product patents were not 
recognized in India between 1972 and 2005, which fostered and stimulated the 
generic drug industry in India.182 This enabled India to supply domestic consump-
tion and export (both developed and developing) affordable generic drugs.183 In 
comparison to South Africa, Van der Walt and Visagie184 found that there has 
been a sharp decline in patent applications from local industry in South Africa, 
whereby the number of patent applications in 2010 was merely 55% of that in 
178 See note 164.
179 See for example s 25(9) of South Africa’s Patents Act 57 of 1978, which provides 
for the patentability of such new uses without any further qualification or conditions.
180 According to Cortes et al 2009 Journal of Clinical Oncology 427 there are no 
major therapeutic differences between Imatinib Mesylate and its new use counterpart. 
181 Busch at (n131) at 113.
182 Lofgren, (2013) The Conversation at 113.
183 S. Musungo, S. Villanueva & R. Blasetti Utilizing trips Flexibilities for pu-
blic health protection through South-South Regional Frameworks, South Centre (2004) 
available at https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.297.6970&rep=re
p1&type=pdf
184 L. Van der Walt & P. Visagie, ‘Patenting in South Africa: Emerging Emergency?’ 
Adams & Adams 1 (2013).
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1990. Furthermore, of the 2442 pharmaceutical patents granted in South Africa 
in 2008, only 16 were held by local companies.185 Whereby locally produced items 
had previously created for about 64% of the country’s domestic requirements, 
imports have increased, resulting in the Pharmaceutical Industry of South Africa 
(piasa) supplying approximately 40% of the local pharmaceutical market of South 
Africa in 2009.186 The top three manufacturers in South Africa- Aspen Pharmacare 
Holdings, Ltd, Adcock Ingram Healthcare (Pty) Ltd and cipla Medpro- only 
take up to 27% of the market share of the South African private sector market.187
Medicine Prices
It is reported that that the entry of Indian firms in the global drug supply market 
lowered the prices of first-time triple combination of antiretroviral (arvs), used in 
the treatment for hiv, from US$15,000 per person annually in the year 2000 to 
less than US$120 in 2012.188 South Africa, on the other hand is in deep financial 
crisis because of expensive medicines. According to ims Health Figures, South 
Africa spent R5 billion in 2012 to procure pharmaceutical products, making the 
procurement of pharmaceuticals the fifth largest contributor of South Africa’s 
trade deficit.189 These showcase that Gauteng’s main import partners are the us 
and Germany, whose market share for imports into Gauteng were respectively 
23.65% and 18.5% in 2013, and worth an accumulated value of nearly R900 
million.190 In total, South Africa spent just over R200,000 million into Gauteng 
alone in 2013. In the extract below, Dr Motsoaledi specifically cites drug prices. 
Such information is very compelling and that is why the 
pae
 had emphasised that 
a debate over individual drug prices was to be avoided.
Extract 4
Dr Motsoaledi:
We have got a cancer drug called Gleevec. This drug costs R876…R876. But in In-
dia, because of trips flexibilities, because it is generic, they pay only R86. We cannot 
be able to get that from India, which is easily accessible to many people who suffer 
cancer. The second example is a tb drug called Linezolid. You know that we have got 
185 C. Tomlinson & L. Rutler, ‘The Economic and social case for patent law reform 
in South Africa’ Fix the Patent Laws 3 (2014). 
186 Gauteng Growth and Development Agency ‘Pharmaceuticals Industry Fact Sheet 
viii’ 3 (2014).
187 Ibid.
188 M. Leis, ‘Death by Treaty: South Africa’s Medicines and Related Substances 
Amendment Act of 1997 and the Agreement on Trade Related Aspects of Intellectual 
Property Rights’, Journal of International Business and Law 13, 12 (2004) 221. Available 
at https://scholarlycommons.law.hofstra.edu/cgi/viewcontent.cgi?article=1034&context=jibl 
189 See note 188.
190 Tomlinson (n187) 4.
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a multidrug resistance to tb. These days tb is a big killer. Linezolid, the original drug 
costs R660 per tablet Tembisa; but in India, it costs R10 per tablet, because of trips 
flexibilities. So in the interests of humanity, if tb is the number 1 killer in the country 
and I want to save human beings, what do you expect me to do?191
Opposition Proceedings: Post and Pre- grant Applications
India employs opposition proceedings. Section 25 of the amended Act192 provides 
for such opposition proceedings. Its pre-grant opposition system is notable in that 
‘any person’ can file for opposition, which has been interpreted to include generic 
drug companies and groups representing patient’s interests in affordable medicines.193 
Therefore, not only do opposition proceedings prevent evergreening by granting 
weak patents, it also provides patent offices with additional input by helping them 
in identifying prior Art examining claims and pointing out which claims are prob-
lematic, and curbing abusive patenting in general. Section 61 of the Patent Act194 of 
South Africa only provides for the possibility of revocation, whereby the application 
is to revoke a patent can only be filed once the patent has already been granted. This 
anti-opposition provision has been addressed in paragraph 1(a) (v) of the Draft IP 
Policy and recommends that South Africa provide for pre and post-grant opposi-
tion to patents. Below Dr Motsoaledi address the negative impact of not having 
opposition proceedings in place regarding patents about other developing countries.
Extract 2
Dr Motsoaledi:
In 2008, only South Africa issued 2722 patents. We are aware that patents are rejec-
ted in Europe and America. Remember Europe and America are very strong patent 
protections. They are very strong. But you are aware that 40% of the patents that are 
rejected there are actually granted in South Africa. That is why we want to come in 
line with the rest of the world.195
Bilateral Trade Agreements
Bilateral Trade Agreements are seen as hindrances to access to medicines in some 
instances when trips-plus obligations are incorporated into them.196 Despite the 
191 See note 179.
192 India Patent Law (as amended by 2005 Act).
193 Novartis (n154) para 108.
194 See note 198.
195 See the interview on note 179.
196 D.S Phiri ‘Economic Partnership Agreements and International Property Right 
Protection: Challenge for sadc Region’ said Occupational Paper n.º 48 (2009) at 136.
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Doha declaration, among its provision, explicitly allowing developing nations 
to issue compulsory licenses or patented pharmaceuticals in response to a public 
health crisis. However, the us aggressively promotes bilateral trade agreements 
with individual developing nations, referred to as trips-plus agreements.197 South 
Africa’s position in this regard has established firm boundaries, as South Africa has 
very clear positions in terms of international trade and investment (going as far as 
denouncing all existing Bilateral Investment Agreements to protect sovereignty). 
The Draft Policy cites instances where certain developing countries are forced to 
concede and agree upon to give up their flexibilities allowed in trips in exchange 
for economic benefits not related to intellectual property and public health.198 In 
coherence with its position regarding international commitments, the policy recom-
mends that South Africa does not enter into such agreements. It even goes further 
and suggests that South Africa actively engages in discouraging other developing 
countries from concluding any trips plus agreement.199 In the extract below, the 
interviewer wants to know what happens when these companies exert pressure on 
the government to force them into bilateral trade agreements:
Extract 6
Tembisa:
But people that are manufacturing these drugs, Minister, are in it for money. So, if 
you are going to intervene with how much profit they can make in a country, then 
you get headlines, like we saw earlier this year, where they are threatening to withdraw 
their investments.
Dr Motsoaledi:
They cannot. They are literally lying. In fact, for your information, India after passing 
the laws and becoming our pharmacy international there is more investments in India. 
They are not pulling out. That is just an idle threat to try and scare us off. Tembisa, let 
me come back to this because you keep talking about people having to make profit. A 
meeting was held between World Trade Organization, World Health Organization and 
World Intellectual Property Organization. World Intellectual Property Organization 
was established, specifically to protect manufacturers, who were profit as you are saying. 
But the World Health Organization was established to protect the health of the people. 
World Trade Organization was established to make trade rules. All these organizations 
197 Kapezynski (n54) at 1059- 6 discusses the U.S commonly negotiates bilateral 
agreements to remove most of the TRIPS flexibilities that were designed to protect 
developing countries.
198 A.D. Mitchell & T. Voon, ‘Patents Public Health in the wto, ftas and Beyond: 
Tension and Conflict in International Law’ Journal of World Trade 43 (2009) 571- 601.
199 Para 1 (a) of the Draft ip Policy at 10.
36     .º 30 -  ju -cb  2020 -  .  5  -  47
Luz Helena Hanauer and Isaac Quinton Ramaphala
fall under the United Nations. All of them are established for the interest of humanity. 
They have met and made agreement on these issues. One of the agreements is that any 
innovation must be to the mutual advantage of the producer and the user. It must be 
for the mutual advantage, because what do you innovate a drug for, if you want me 
to touch it, because it is too expensive for me to use? What was your initial reason of 
innovating, if it is beyond my reach? If it is beyond the reach of citizens?
Antiretroviral Treatment
South Africa
To date, South Africa has the largest Antiretroviral (art) programme in the world. 
In 2019, unaids reported that 4, 4 million people were receiving treatment in 
South Africa.200 This encapsulates to 61% of the people living with hiv in the 
country.201 South Africa’s art services have recently undergone significant expan-
sion, in keeping with the World Health Organization (who) guidelines. In 2016, 
South Africa implemented ‘test and treat’, whereby everyone with a positive di-
agnosis was eligible to start treatment. This has meant that the number of people 
eligible for treatment has increased from 3,39 million in the middle of 2015 to 
7,1 million in 2016- more than double in a short period of time.202
India
India has the third-largest epidemic in the world. In 2017, hiv prevalence 
among adults (aged 15- 49) was an estimated 0, 2%. This figure is small compared 
to most other middle-income countries but because of India’s huge population (1, 
3 billion), this equates to 2, 1 million people living with hiv.203 Overall, India’s 
hiv epidemic is slowing down. Between 2010 and 2017, new infections declined 
by 27% and aids-related more than halved, falling by 56%.204 However, in 2017, 
new infections increased to 88,000 from 62,000.205
Botswana
In the context of the law of Patents, it is important to record that Botswana is 
a part to the following international/regional agreements: Berne Convention;206 
200 unaids data, 2019.
201 Ibid.
202 Network for Analysis of Longitudinal Population – based hiv/aids data on Africa. 
Special Analysis for unsaids. In: Get on the Fast- Track: the life cycle approach to hiv. 
Geneva; unaids; 2016.
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Harare Protocol (aripo);207 Paris Convention;208 Patent Corporation Treaty;209 and 
wto/ trips Agreement.210
The current Patent Law of Botswana is contained in the Industrial Property Act 
(the Act),211 which was approved by the President on 26 April 2010 and came into 
operation on 31 August 2012.212 The legislation allows patenting of new inventions 
involving an inventive step. Further, such inventions may relate to both products 
and processes.213 Section 2 differentiates between an invention and a patent in its 
interpretation section and defines an invention as an idea of an inventor which in 
practice may be used as a solution to a specified problem. Patents may be granted 
for 20 years214 from the date of filing an application.215
Pre- Grant Opposition Applications
It is noteworthy to envisage that section 21 of the Act provides for pre-grant opposi-
tion to patent and examination of patents for technical quality.216 Once the patent 
application has been published in the patents journal,217 members of the public, 
including those with technical know-how of the field to which the patents relates, 
may oppose the grant of the patent on the number of listed grounds.218 One of the 
grounds relevant to medicines provided in section 21 (5) (a) to (c) may be that the 
invention does not meet the requirements of patentability as specified in the Act.
Parallel Imports
Section 25 of the Act adopts the international exhaustion of rights regime which 
allows for paralleled imports. The relevant provision regards acts in respect of ar-
ticles that have been put on the market in Botswana or abroad by the patentee or 
another person acting with the patentee’s consent as exceptions to rights conferred 
by a patent.219 This means that in Botswana it is permitted by its regulations to 
import cheap medicines from international and regional markets provided that the 
product has been placed on the said markets by the patentee himself or by some-
one acting on behalf of the patentee with his/her permission.220 In other words, 
207 Since 1985.
208 Since 15 April 1998.
209 Since 30 October 2003.
210 Since 31 May 1995.
211 Act 8 of 2010.
212 See the Industrial Property Act Order 12, available at http://wipo.int/wipolex/en/
text.jsp?file_=277945 last accessed 11/12/2019.
213 The following are provisions of the Patent Act.
214 Section 28 of the Act.
215 Section 28 (1) of the Act.
216 Section 20 of the Act provides that the filing date is the date of application.
217 Section 21 (a) of the Act.
218 Section 21 (5) (a)- (c).
219 Section 25 (1) (a) of the Act.
220 The interpretation of section 21 (a).
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Botswana allows for comparative shopping in an attempt to increase affordability 
and expose the Botswanan market more widely.
Compulsory Licenses
The Act contains extensive provisions on compulsory licenses. In general, compul-
sory licenses may be issued for: public interests or for competition;221 importing 
patented products in the context of trips Article 31 bis;222 to remedy a failure 
to exploit the patent223 and to deal with dependent patents.224 Public interest 
grounds for the issuance of compulsory licenses include national security, health, 
development and other vital sectors of Botswana’s national economy.225 Section 
31 (1) envisages that the Minister may, without the patentee’s consent but after 
hearing him/her, authorize a government agency remuneration of the patentee.226 
If the compulsory license is issued in response to anti-competitive practices,227 the 
determination/ calculation of the remuneration will have to take into account the 
economic value of the exploitation of the patent. According to section 31 (1) of the 
Act, in cases of national emergency or circumstances of extreme urgency (which 
is not defined), there is no need for the applicant for a compulsory license to have 
requested a voluntary license on reasonable terms.
It is of paramount importance to observe that where compulsory licenses are 
issued in the public interest,228 the ‘exploitation of the patented invention shall be 
for the supply of the domestic market in Botswana only, except when paragraph 1 
or 3 of Article 31 bis of the trips Agreement applies.’229 Additionally, sections 32 
(1) (a) (b) grant the government of Botswana power to issue a compulsory license 
to a third party to import patented products such as pharmaceutical generic drugs 
from any legitimate source without approval of the patentee for public interest or 
in a situation of a failure to supply the market. Therefore, the importation of the 
product shall be only for the public non- commercial use within Botswana, except 
where paragraph 1 or Article 31 bis of the trips Agreement applies.230 This means 
that the whole section 32 of the Industrial Property Act of Botswana incorporates 
within the domestic framework the provisions of Article 31 bis of trips.
221 Section 31 of the Act.
222 Section 31 (1) of the Act. See also Ndlovu (note 6)
223 Section 33 of the Act.
224 Section 34 of the Act.
225 Section 31 (1) (a) of the Act.
226 Ibid.
227 Under section 31 (i) (a).
228 Section 31 (3).
229 Article 32 (2) of trips.
230 unaids Data Report, 2019.
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Antiretroviral Treatment
The impact of Botswana’s treatment programme has been widespread. According 
to the unaids Report of 2019, new infections have decreased significantly, from 
18,000 in 2005, to 10,000, and down to 8,500 in 2018. 231 aids-related deaths 
have also dramatically decreased from a peak of 18,000 recorded in 2000 to 4,800 
in 2018.232 Botswana is the first country in the region to provide a universal free 
antiretroviral treatment to people living with hiv. Its antiretroviral programme in 
Sub- Saharan Africa has been one of the most successful. By 2016, it was estimated 
that 298,000 adults living with hiv were receiving antiretroviral- a coverage of 
85% up from 77% in 2015.233 Coverage among children has reached 60% and the 
proportion of people living with hiv who have suppressed viral loads was 78%.234
Zimbabwe
The Zimbabwe’s Patents Act (the Patents Act),235 defines an invention as follows:
‘Invention means any new and useful art, whether producing a physical effect 
or not, or process, machine, manufacture or composition of matter which is not 
obvious or any new useful improvement thereof which is not obvious, capable of 
being used or applied in trade or industry and includes an alleged invention.’236 A 
patent, which means letters patent for an invention granted for Zimbabwe under 
section 21,237 is granted to an inventor for 20 years from the date of the lodgement 
of the application patent238 and is binding against the state and individuals.239
Pre- Post Grant Opposition Applications
The granting of a patent may be opposed within 3 months of the publication 
of a complete specification in the patent’s journal but before it is accepted in terms 
of section 16 of the Act.240 Any interested persons including the state may oppose 
the granting of a patent and the application for the opposition may be submit-
ted to the Registrar who will deal with it after hearing the patentee.241 14 listed 
grounds may be raised to oppose the granting of a patent but not all are relevant 
231 Ibid.
232 Ibid.
233 Centres for Disease Control and Prevention. Differences between hiv- infected 
men and women in antiretroviral therapy outcomes- six African countries, 2004- 2012. 
mmwr Morb Mortel Weekly Rep. 2013; 62 (47); 946-52.
234 unaids Data Report, 2019.
235 Patents Act 26.03 of 1972, last amended in 2002 (the Act to be considered below).





241 Section 17 (1).
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for access to medicines. The ones relevant are those relating to inventions that are 
not useful; inventions that are obvious and involve no inventive step having regard 
to the state of the art; and those brought to the attention of Registrar through an 
application form containing a material misrepresentation.
Compulsory Licenses
In terms of the Patent Act, compulsory licenses are provided for in sections 30 – 
35. The various instances that may trigger the application for a compulsory license 
may be based on any of the following grounds: to deal with dependant patents;242 
to curb patent abuse and non- use of patents;243 to deal with inventions relating 
to food, medicine, or other commodities;244 to deal with the use of patented in-
ventions for the service of the state, and to deal with government use of patents 
during periods of emergency.245
Section 35 of the Act states that during an emergency, a person or government 
department may be authorized by the state to make use, exercise, or rend an inven-
tion without the patentee’s prior authorization. In this specific context of national 
emergencies, the authorization may be granted in the following circumstances rel-
evant to access to medicines: for the maintenance of supplies and services essential 
for the life of the community;246 for the promotion of productivity of industry, 
commerce or agriculture;247 for ensuring that whole resources of the community 
are available for use and are used in assisting the relief of suffering and the restora-
tion of distribution of essential supplies and services in any part of Zimbabwe or 
any other country that is in grave distress because of war.248 
The government of Zimbabwe has successfully used the special provisions 
during an emergency249 in its Patent Act to supply affordable drugs to hiv/aids 
positive patients in the country.
In 1999, unaids considered Zimbabwe to be with one of the highest hiv/aids 
infection rates in the whole world.250 Nonetheless, by 2012, the country had turned 
the tide and reached a decline in hiv prevalence, from 27% in 1997 to about 14% 
in 2010.251 Before this, it was estimated that 1,5 million people were living with 




245 Section 35 (1) (b). See also Ndlovu (note 6).
246 Section 35 (1) (a).
247 Section 31 (1) (f ).
248 Section 35 (1) (g).
249 Generally provided for in section 35 of the Patent Act.
250 Network for Analysis of Longitudinal Population- based on hiv/aids data on Africa 
(alpha). Special Analysts for usaids. In: Get on the Fast Track: the life Cycle approach 
to hiv. Geneva; unaids; 2016
251 usaids Data Report, 2019.
252 Ibid. See also L. Ndlovu (n.6).
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180 000 hiv/aids-related deaths annually, and more than 1, 1 million children 
had been orphaned due to hiv/aids. Zimbabwean officials invoked the govern-
ment’s use of provisions in the Patent Act to make available hiv/aids medication 
for its affected population. The Patent law provides for government use of patents 
generally and during a state emergency and such uses are sanctioned by Article 
31 (b) of trips for public non- commercial purposes, therefore, the Zimbabwean 
law contains a trips foundation.253 It is important that with specific reference to 
‘the period of emergency’ in patent law, the beginning and end of the period is 
dependent entirely on the Minister’s discretion hence he/she has wide discretion 
to issue a compulsory license in times of emergency.254
Patent protection had made antiretroviral (arv) drugs such as GlaxoSmith-
Kline’s zidovudine, lamivudine, and nevirapine made by Boehringer- Ingelheim 
(bi) were very expensive and out of reach for many Zimbabwe’s poor.255 In May 
2007, the Minister of Justice, Legal and Parliamentary Affairs issued a notice of 
declaring six months of emergency on hiv/aids.256 The notice was later extended 
from January 2003 to December 2008.257 The extension of the period was fol-
lowing the government policy to promote the manufacturing and importing of 
generic hiv/aids drugs.258 The notice would enable the government or any other 
person authorized by the Minister ‘to import any generic used in the treatment 
of persons suffering from hiv/aids or hiv/aids related conditions.’259 Under the 
notice, Varichom, a local pharmaceutical manufacturing company, was nominated 
by the Minister and the company agreed to provide antiretroviral or hiv/aids 
drugs and to supply three- quarters of its produced drugs to state-owned health 
institutions at fixed prices. The company introduced its generic drugs late in 
2003.260 The introduction of generics into the market lowered the price of arvs 
from US$1,168 to US$412 per patient per year due to increased competition and 
yielded positive results for access to medicines in Zimbabwe.261
253 Article 31 (b) of trips.
254 J. Fumorodze, ‘The wto trips Agreement on Access to Medicines in South Africa’ 
Botswana Law Journal 13 (2011) at 96.
255 Fumorodze laments that the fact that a triple combination with azt/3tct nevarapine 
cost US$1,168 per patient per year beyond the reach of an average Zimbabwean where 
the majority lived on less than US$1 per day.
256 Ibid. Also see note 256.
257 General Notice 240 of 2002 issued in terms of the Patent Act [Chapter 26: 03} 
under the title Declaration of Period of Emergency (hiv/aids) Notice of 2002. See para 
2 (a) (b) of the Notice. See also L. Ndlovu (n. 6).
258 Fumorodze, see (n 256).
259 Ibid.
260 Ibid.
261 cptech citing a report from Médecins Sans Frontiers at http://www.cptech.org/
ip/health/c/zimbabwe 
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Antiretroviral Treatment
According to the unaids Report of 2019, Zimbabwe has 38,000 new hiv infec-
tions. The percentage of adults on arv is 89% and 76% for children, with a 12, 
7% adult hiv prevalence. This is a significant decrease considering the prevalence 
of 14% in 2010 mentioned above.
5. availability of patents pharmaceuticals 
and new use patents in africa
A sizable number of African countries, especially those within the sadc region, al-
low patents for the new use of known medicines, most do it by enacting legislation 
that provides for the granting of patents. This is done mostly without including an 
express reference to the prohibition of new use of known substances. Only three 
countries, namely Malawi,262 Namibia263, and Zambia,264 have provisions in their 
legislation specifically prohibiting the patenting of a new use forms of substance 
in their pharmaceutical context265.
Malawi
Section 18 of Malawi’s Patent Act, Chapter 49: 02 excludes the patenting of in-
ventions ‘capable of being used as food or medicine’ and are a mixture of known 
ingredients possessing only the aggregate of known properties of the ingredients.
Namibia
Sections 17 (1) (j) - (k) and 17 (2) of the Industrial Property Act of 2012 exclude 
the patenting of a new use of patents.
Zambia
The Zambian Patent Act, last amended in 1987, generally does not exclude the 
new use except that in cases where the inventions capable of being used as food or 
medicine in a similar forbidding context as provided for in Malawi law.
262 Section 18 of the Malawian Patent Act.
263 Sections 17 of the Industrial Property Act of Zambia.
264 Section 18 (1) of the Zambian Patent Act.
265 Supra L. Ndlovu (n.6) p. 170.
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6. conclusion 
This document has explored the landscape of ip regulations in South Africa, ex-
plaining its rich history and specific contextual background and providing a brief 
comparison with peer countries in the sub-Saharan region. It has drawn the obliga-
tory comparison with India, which has played a pivotal role in the construction 
of regulations, narratives, and interpretations of ip regulations in similar contexts.
One additional issue to consider is the treatment of Least Developed Countries 
(ldc). It is approximately more than 50% of sadc members least developing coun-
tries which are not obliged to comply with the trips requirements for patenting 
of pharmaceuticals. Yet all of these countries permit pharmaceutical patents. A 
compelling factor to consider by African nations is that India today is known as 
the Pharmacy of the world because it provided for generic medicines from its local 
market for a long time for its population before complying with the requirements 
of trips in 2005. Therefore, what should be investigated is why least developed 
countries did not use of the opportunity afforded to them by the extension of the 
transition period266 by the trips Council.
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